



14

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 48/00, C12Q 1/68	A1	(11) International Publication Number: WO 97/09069
		(43) International Publication Date: 13 March 1997 (13.03.97)
(21) International Application Number: PCT/SE96/01119 (22) International Filing Date: 6 September 1996 (06.09.96) (30) Priority Data: 9503117-5 8 September 1995 (08.09.95) SE (71)(72) Applicant and Inventor: LANDEGREN, Ulf [SE/SE]; Eksoppsvägen 16, S-756 46 Uppsala (SE). (74) Agents: ALDENBÄCK, Ulla et al.; Dr. Ludwig Brann Patentbyrå AB, P.O. Box 1344, S-751 43 Uppsala (SE).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, I ...), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>

(54) Title: **METHODS AND COMPOSITIONS FOR NUCLEIC ACID TARGETING**

(57) Abstract

The present invention relates to methods and compositions for targeting nucleic acid sequences, more specifically double stranded nucleic acid sequences. The compositions comprise oligonucleotides in the form of padlock probes. The padlock probes have two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence. Furthermore, the invention relates to use of said compositions as medicaments for treating genetic disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

WO 97/09069

PCT/SE96/01119

1

METHODS AND COMPOSITIONS FOR NUCLEIC ACID TARGETING

Field of the invention

The present invention relates to methods and pharmaceutical compositions for targeting nucleic acid sequences, more specifically double stranded nucleic acid sequences. The compositions comprise oligonucleotides in the form of so called padlock probes. The padlock probes have two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence. Furthermore, the invention relates to use of said compositions as medicaments for treating genetic disorders.

Background of the invention

Oligonucleotides as potential therapeutics has developed by the ability to synthesize oligonucleotides, chemically modified oligonucleotide analogs and conjugated oligonucleotides, of suitable quantity and purity, as a result of the now ready availability of oligonucleotides through automated synthesis using, for example, the phosphoramidite method.

A first approach to therapeutic use of oligonucleotides is to use them as inhibitors of translation, with the complementary or 'antisense' base sequence targeted to a specific 'sense' sequence in the mRNA. In this way, expression of a specific protein can be regulated or inhibited.

Mechanisms of antisense inhibition include interference with ribosome binding and processing of mRNA conformation or mRNA splicing, and RNAase-H activation of mRNA digestion. The preferred target for antisense inhibition is the 5'-initiation codon.

A second approach to therapeutic use of oligonucleotides is to target DNA therewith and thereby directly inhibit gene function by inhibiting transcription to mRNA. In contrast to mRNA which,

CONFIRMATION

WO 97/09069

PCT/SE96/01119

2

although extensively folded, is readily accessible, the DNA duplex is very stable which complicates inhibition thereof.

One way of solving the problem with inaccessibility of double stranded DNA is to take advantage of the fact that a third strand can be accommodated in the major groove of the B-form DNA duplex to form a triplex structure.

Duplex recognition by an oligonucleotide involves the formation of two hydrogen bonds with the purines of Watson-Crick base pairs within the major groove of the double helix. Thymine, cytosine, and guanine can adopt two different orientations called 'Hoogsteen' and 'reverse Hoogsteen' by analogy with the hydrogen-bonding scheme discovered by Hoogsteen in co-crystals of A and T derivatives. In contrast, adenine and inosine can form two hydrogen bonds with and A.T base pair in a single orientation. It should be noted that in order to form two hydrogen bonds with G, cytosine must be protonated. Therefore, triplets involving C+ x G.C are more stable at acidic pH. Methylation at C-5 of cytosine also contributes to stabilization of the triple helix.

Several mechanisms exist by which triple helix formation can alter gene transcription:

1. Triple helix formation within the promoter region can change DNA conformation and therefore alter the rate and efficiency of RNA polymerase initiation. This can lead to either activation or inhibition of transcription.
2. Oligonucleotide binding to a DNA sequence overlapping a transcription factor binding site may inhibit its transactivating capacity.
3. Triplex formation within or adjacent to the region where RNA polymerase binds may inhibit transcription initiation even if RNA polymerase and transcription factors are still bound to the promoter.
4. Oligonucleotide binding downstream of the RNA polymerase recognition site might inhibit progression of the transcription machinery along the DNA and therefore block RNA elongation.

Targeting by triple helix formation is limited to only a particular subset of DNA sequences, such as those associated with homopurine-homopyrimidine tracts.

An alternative way of directly inhibiting DNA is described in Nucleic Acids Research, 1993, Vol 21, No 2, p 197-200 to Nielsen et al. The authors describe that PNA (peptide nucleic acids chimera), i.e., DNA analogues in which the deoxyribose phosphate backbone has been replaced with a peptide backbone consisting of (2-amoniethyl)glycine units have retained the hybridization properties of DNA. There is shown that PNA binds more strongly to complementary oligonucleotides than DNA itself. Moreover, PNA can bind sequence specifically to double stranded DNA. This binding takes place by strand displacement rather than by triple helix formation. In brief, a rather unstable strand displacement complex is first formed with only one PNA molecule bound to the target by Watson-Crick hydrogen bonding, and this is subsequently trapped by binding of a second PNA molecule via Hoogsteen hydrogen bonding.

However, because of their relatively strong binding the sequence specificity rapidly diminishes with the increasing length of the PNA probes.

Branch capture reactions (BCRs) target duplex restriction fragments terminating in overhanging bases with short homologous single stranded DNA oligonucleotides that can pair with the unpaired overhanging bases and some flanking sequence so that complete base pairing displaces the end of one resident strand by branch migration. The limitation of BCRs is that they are limited to targeting only known terminal sequences and are, thus, not very suitable as therapeutic agents.

In Nature Genetics, vol. 3, april 1993, there is described another probe-targeting method which uses Rec A protein-coated short single stranded DNA probes to form four stranded hybrids between probes and duplex DNA targets. With this method in-

ternally localized sites can be targeted and the four stranded hybrids are stable.

All the above nucleic acid targeting methods suffer from drawbacks the most important one being the insufficient sequence specificity of the probes. This is an especially essential consideration in respect of the potential use of the probes as therapeutics.

Summary of the invention

The present invention is derived from the copending international application no. PCT/SE95/00163 entitled: Method, reagent and kit for detection of specific nucleotide sequences. This application is referred to and herein incorporated by reference. In this application so called padlock probes are described.

In summary, said application describes a probe designed to be circularized in the presence of a target sequence, wherein said probe is caused to close around the target nucleic acid, for example DNA or RNA, such that the cyclic probe will interlock with and thereby be efficiently linked to the target nucleic acid in a manner similar to "padlocks". The circularization of the probe ends is achieved with, for example, ligase. Such covalent catenation of probe molecules to target sequences result in the formation of an extremely stable hybrid.

It has now been surprisingly found that these padlock probes are able to affect gene function directly by binding to double stranded nucleic acids, without a prior denaturation step, and thereby affect the replication and transcription of the bound molecule. This is expected to provide new therapeutic possibilities for in vivo manipulation of gene sequences and treatment of genetic disorders.

In a first aspect, the present invention provides a method for targeting double stranded nucleic acids, comprising the following steps:

a) contacting a linear padlock probe having two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence;

with a double stranded nucleic acid target without prior denaturation of said target;

b) hybridizing said free nucleic acid end parts with said two at least substantially neighboring respective regions of a target nucleic acid sequence; and

c) circularization of said padlock probe by joining said free end parts.

The joining in step c) is performed with a linking agent such as a ligase enzyme or mutually chemically reactive compounds at the free end parts.

The method of the invention can be performed both in vitro and in vivo.

According to a second aspect, the present invention provides a pharmaceutical composition for targeting double stranded nucleic acids, comprising an effective amount of a padlock probe oligonucleotide having two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence so that the padlock probe can be circularized by joining said free end parts and catenate with the target sequence for direct inhibition thereof.

The composition is preferably formulated in admixture with a suitable carrier, such as conventional pharmaceutically acceptable carriers known in the art.

According to a third aspect of the invention the above described

compositions are used as a medicament for treating genetic disorders.

Detailed description of the invention

Padlock probe targeting to double stranded DNA according to the method of the invention optionally involves a linking agent which can be chemical or biological. It is, for example, a ligase-assisted reaction. The principle employed in such a reaction is that a linear two-probe segment with a probe in each end, complementary to two target sequences situated in juxtaposition, are joined to a contiguous circular probe sequence with the aid of a linking agent, such as a DNA ligase. Examples of ligases are T4 DNA ligase, T7 DNA ligase, E.coli DNA ligase, and *Thermus thermophilus* DNA ligase. Also groups that are mutually chemically reactive may be used to join the ends of the probes in an enzyme-independent manner. This way of joining oligonucleotide ends has been previously used in the art. Besides ligases, proteins like RecA or single strand-binding protein can enhance the ability of circularizable probes to hybridize and become catenated to, base paired DNA.

The compositions according to the invention may or may not contain a linking agent depending on the use of the compositions. In vivo, RecA and DNA ligase are already present, and thus the addition of a linking agent may not be necessary for therapeutic applications.

According to the present invention, padlock probes are used in in vitro methods to specifically detect DNA sequences within a cell, without a requirement for prior denaturation. In this manner, for example, the correct spatial relations between specific DNA sequences can be analyzed without artificially induced effects.

In the in vitro method of the invention, probes of this type could also be used to modify and thereby mutate specific genes in in vitro cell lines, and for instance in embryonal stem cells

to give rise to transgenic animals carrying mutations in predefined genes.

In all these various applications, the effects of the padlock probes may be accentuated by at least partially building the probes of non-natural nucleic acids, or of polymers such as PNA, having advantages such as stronger base pairing, greater resistance to nucleases, or increased ability to cross cell membranes.

Padlock probes bind selectively and stably to double stranded DNA and enable sequence specific modification of DNA. In fact, it is contemplated that padlock probes even will be able to selectively bind gene sequence variants with point mutations, in order to inhibit the expression of the mutant genes, since the ligation is dependent upon the exact target sequence. The increased specificity is achieved by the fact that two shorter probe segments have to cooperate for binding to occur. A further advantage is that padlock probes are not sensitive to exonucleases due to their circular shape when they are ligated. On the other hand, excess of padlock probes is rapidly degraded by exonucleases which is a benefit in, for example, drug formulation.

The invention will now be illustrated further, by way of example only, by the following non-limiting specific Examples.

EXAMPLE 1

Padlock probe binding to double stranded nucleic acid target

A padlock probe oligonucleotide having the following sequence: 5' P-TGG TGT TTC CTA TGA-((HEG₂)C-B)₂-(HEG)₂-AAG AAA TAT CAT CTT-3', wherein P is a phosphate residue, HEG is hexaethylene glycol and C-B is a biotinylated C residue, was synthesized using a commercial DNA synthesizer. The two ends of the oligonucleotide were capable of base-pairing adjacent to each other with exon 9 of the CTFR gene contained in the double stranded plasmid pUC 19.

CLAIMS

1. A method for targeting double stranded nucleic acids, comprising the following steps:

a) contacting a linear padlock probe having two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence;

with a double stranded nucleic acid target without prior denaturation of said target;

b) hybridizing said free nucleic acid end parts with said two at least substantially neighboring respective regions of a target nucleic acid sequence; and

c) circularization of said padlock probe by joining said free end parts.

2. Method according to claim 1, wherein the joining in step c) is performed with a linking agent.

3. Method according to claim 2, wherein the joining in step c) is performed with a ligase enzyme.

4. Method according to claim 1 or 2, wherein the joining step is achieved by mutually chemically reactive compounds at said probe end parts.

5. Method according to any of claims 1-4 which is an in vitro method.

6. Method according to any of claims 1-4 which is an in vivo method.

7. A pharmaceutical composition for targeting double stranded nucleic acids, comprising an effective amount of a padlock probe oligonucleotide having two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence so that the padlock probe can be circularized by joining said free end parts and catenate with the target sequence for direct inhibition thereof.

8. A composition according to claim 7, also comprising a linking agent.

9. A composition according to claim 8, wherein linking agent is a ligase enzyme.

10. A composition according to claim 7, comprising mutually chemically reactive compounds at said end parts.

11. A composition according to any of claims 7-10, in admixture with a suitable carrier.

12. A composition according to any of claims 7-11, wherein said padlock probe comprises non-natural nucleic acids or polymers.

13. A composition for targeting nucleic acids, comprising an effective amount of a padlock probe having two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence so that it can be circularized and catenate with the target sequence, for use as a medicament.

AMENDED CLAIMS

[received by the International Bureau on 17 January 1997 (17.01.97);
original claims 1 - 13 replaced by amended claims 1 - 7 (1 page)]

1. A pharmaceutical composition for targeting double stranded nucleic acids, characterized in that it comprises an effective amount of a padlock probe oligonucleotide having two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence so that the padlock probe can be circularized by joining said free end parts and catenate with the target sequence for direct inhibition thereof.
2. A composition according to claim 1, in admixture with a suitable carrier.
3. A composition according to claim 1, also comprising a linking agent.
4. A composition according to claim 3, wherein linking agent is a ligase enzyme.
5. A composition according to claim 1, comprising mutually chemically reactive compounds at said end parts.
6. A composition according to any of claims 1-5, wherein said padlock probe comprises non-natural nucleic acids or polymers.
7. A composition for targeting nucleic acids, comprising an effective amount of a padlock probe having two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with two at least substantially neighboring respective regions of a target nucleic acid sequence so that it can be circularized and catenate with the target sequence, for use as a medicament.

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 48/00, C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K, C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, MEDLINE, BIOSIS, DBA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Science, Volume 265, Sept 1994, Mats Nilsson et al, "Padlock Probes: Circularizing Oligonucleotides for Localized DNA Detection" page 2085	1-6
A	-----	7-13

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

26 November 1996

Date of mailing of the international search report

09 -12- 1996

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson
Telephone No. +46 8 782 25 00